Neurocrine Biosciences (NBIX) Operating Leases (2019 - 2021)
Historic Operating Leases for Neurocrine Biosciences (NBIX) over the last 3 years, with Q3 2021 value amounting to $121.9 million.
- Neurocrine Biosciences' Operating Leases rose 3149.95% to $121.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $121.9 million, marking a year-over-year increase of 3149.95%. This contributed to the annual value of $94.4 million for FY2020, which is 888.12% up from last year.
- As of Q3 2021, Neurocrine Biosciences' Operating Leases stood at $121.9 million, which was up 3149.95% from $124.0 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Operating Leases registered a high of $124.0 million during Q2 2021, and its lowest value of $66.2 million during Q2 2019.
- Over the past 3 years, Neurocrine Biosciences' median Operating Leases value was $92.7 million (recorded in 2020), while the average stood at $93.3 million.
- The largest annual percentage gain for Neurocrine Biosciences' Operating Leases in the last 5 years was 4127.07% (2020), contrasted with its biggest fall of 888.12% (2020).
- Over the past 3 years, Neurocrine Biosciences' Operating Leases (Quarter) stood at $86.7 million in 2019, then rose by 8.88% to $94.4 million in 2020, then increased by 29.13% to $121.9 million in 2021.
- Its Operating Leases stands at $121.9 million for Q3 2021, versus $124.0 million for Q2 2021 and $119.7 million for Q1 2021.